Department of Pediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; Internal Medicine C, University Medical Center Greifswald, 17475 Greifswald, Germany.
Mol Cell. 2022 Mar 17;82(6):1140-1155.e11. doi: 10.1016/j.molcel.2022.02.013. Epub 2022 Mar 3.
MLL rearrangements produce fusion oncoproteins that drive leukemia development, but the direct effects of MLL-fusion inactivation remain poorly defined. We designed models with degradable MLL::AF9 where treatment with small molecules induces rapid degradation. We leveraged the kinetics of this system to identify a core subset of MLL::AF9 target genes where MLL::AF9 degradation induces changes in transcriptional elongation within 15 minutes. MLL::AF9 degradation subsequently causes loss of a transcriptionally active chromatin landscape. We used this insight to assess the effectiveness of small molecules that target members of the MLL::AF9 multiprotein complex, specifically DOT1L and MENIN. Combined DOT1L/MENIN inhibition resembles MLL::AF9 degradation, whereas single-agent treatment has more modest effects on MLL::AF9 occupancy and gene expression. Our data show that MLL::AF9 degradation leads to decreases in transcriptional elongation prior to changes in chromatin landscape at select loci and that combined inhibition of chromatin complexes releases the MLL::AF9 oncoprotein from chromatin globally.
MLL 重排产生融合癌蛋白,驱动白血病的发展,但 MLL 融合失活的直接影响仍未明确定义。我们设计了可降解的 MLL::AF9 模型,其中小分子治疗可诱导快速降解。我们利用该系统的动力学,确定了一组核心的 MLL::AF9 靶基因,其中 MLL::AF9 降解在 15 分钟内诱导转录延伸的变化。随后,MLL::AF9 降解导致转录活性染色质景观的丧失。我们利用这一见解来评估靶向 MLL::AF9 多蛋白复合物成员的小分子的有效性,特别是 DOT1L 和 MENIN。DOT1L/MENIN 联合抑制类似于 MLL::AF9 降解,而单一药物治疗对 MLL::AF9 占有率和基因表达的影响则更为温和。我们的数据表明,MLL::AF9 降解导致特定基因座的转录延伸减少,然后染色质景观发生变化,联合抑制染色质复合物可使 MLL::AF9 癌蛋白从染色质上整体释放。